Legal & General Group’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $14.3M | Sell |
135,367
-13,797
| -9% | -$1.22M | ﹤0.01% | 960 |
|
|
2025
Q4 | $13M | Sell |
149,164
-6,665
| -4% | -$546K | ﹤0.01% | 1023 |
|
|
2025
Q3 | $10.4M | Sell |
155,829
-10,352
| -6% | -$588K | ﹤0.01% | 1196 |
|
|
2025
Q2 | $9.18M | Buy |
166,181
+18,074
| +12% | +$867K | ﹤0.01% | 1239 |
|
|
2025
Q1 | $7.16M | Sell |
148,107
-4,455
| -3% | -$187K | ﹤0.01% | 1326 |
|
|
2024
Q4 | $5.89M | Sell |
152,562
-444
| -0.3% | -$19.4K | ﹤0.01% | 1497 |
|
|
2024
Q3 | $6.89M | Buy |
153,006
+99,720
| +187% | +$4.03M | ﹤0.01% | 1404 |
|
|
2024
Q2 | $1.85M | Buy |
53,286
+2,600
| +5% | +$76.1K | ﹤0.01% | 1977 |
|
|
2024
Q1 | $1.47M | Buy |
50,686
+5,397
| +12% | +$147K | ﹤0.01% | 2051 |
|
|
2023
Q4 | $1.04M | Buy |
45,289
+524
| +1% | +$9.17K | ﹤0.01% | 2193 |
|
|
2023
Q3 | $747K | Buy |
44,765
+265
| +0.6% | +$5.14K | ﹤0.01% | 2286 |
|
|
2023
Q2 | $1.23M | Buy |
44,500
+25,364
| +133% | +$635K | ﹤0.01% | 2129 |
|
|
2023
Q1 | $440K | Buy |
19,136
+4,728
| +33% | +$79.4K | ﹤0.01% | 2355 |
|
|
2022
Q4 | $157K | Buy |
14,408
+1,118
| +8% | +$9.43K | ﹤0.01% | 2697 |
|
|
2022
Q3 | $112K | Sell |
13,290
-4,836
| -27% | -$45.8K | ﹤0.01% | 2785 |
|
|
2022
Q2 | $143K | Sell |
18,126
-3,468
| -16% | -$41.9K | ﹤0.01% | 2753 |
|
|
2022
Q1 | $511K | Buy |
21,594
+330
| +2% | +$9.3K | ﹤0.01% | 2391 |
|
|
2021
Q4 | $727K | Buy |
21,264
+632
| +3% | +$20K | ﹤0.01% | 2313 |
|
|
2021
Q3 | $365K | Buy |
20,632
+8,071
| +64% | +$344K | ﹤0.01% | 2509 |
|
|
2021
Q2 | $563K | Buy |
12,561
+2,016
| +19% | +$66.5K | ﹤0.01% | 2317 |
|
|
2021
Q1 | $273K | Buy |
10,545
+233
| +2% | +$5.9K | ﹤0.01% | 2397 |
|
|
2020
Q4 | $208K | Buy |
10,312
+6,696
| +185% | +$144K | ﹤0.01% | 2412 |
|
|
2020
Q3 | $71K | Sell |
3,616
-106
| -3% | -$1.99K | ﹤0.01% | 2582 |
|
|
2020
Q2 | $66K | Buy |
3,722
+1,033
| +38% | +$13K | ﹤0.01% | 2644 |
|
|
2020
Q1 | $19K | Sell |
2,689
-822
| -23% | -$6.16K | ﹤0.01% | 2930 |
|
|
2019
Q4 | $25K | Buy |
3,511
+426
| +14% | +$4.23K | ﹤0.01% | 3120 |
|
|
2019
Q3 | $37K | Buy |
3,085
+555
| +22% | +$7K | ﹤0.01% | 2868 |
|
|
2019
Q2 | $31K | Buy |
+2,530
| New | +$28K | ﹤0.01% | 3001 |
|
|
2018
Q2 | – | Sell |
-2,205
| Closed | -$19K | – | 3378 |
|
|
2018
Q1 | $19K | Hold |
2,205
| – | – | ﹤0.01% | 3126 |
|
|
2017
Q4 | $46K | Buy |
2,205
+487
| +28% | +$8.64K | ﹤0.01% | 2893 |
|
|
2017
Q3 | $30K | Buy |
1,718
+691
| +67% | +$9.57K | ﹤0.01% | 3060 |
|
|
2017
Q2 | $12K | Hold |
1,027
| – | – | ﹤0.01% | 3297 |
|
|
2017
Q1 | $13K | Sell |
1,027
-316
| -24% | -$5.09K | ﹤0.01% | 3161 |
|
|
2016
Q4 | $30K | Buy |
+1,343
| New | +$29.9K | ﹤0.01% | 3028 |
|
Other funds holding PTGX
FCM
RI
VPM
VCM
JJ
Legal & General Group's PTGX Position: Q1 2026 in Review
Legal & General Group reduced its Protagonist Therapeutics (PTGX) stake by 9.2% in Q1 2026, selling an estimated $1.22M and leaving 135,367 shares worth $14.3M. The position accounts for ﹤0.01% of the portfolio, ranked #960.
Legal & General Group first reported a position in PTGX in Q4 2016 and has held it in 34 quarters since. 318 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.
- Legal & General Group held 135,367 shares of Protagonist Therapeutics worth $14.3M as of Q1 2026.
- Legal & General Group sold 13,797 Protagonist Therapeutics shares in Q1 2026, an estimated $1.22M.
- Protagonist Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #960 holding.
- Legal & General Group first reported a position in Protagonist Therapeutics in Q4 2016 and has held it in 34 quarters since.
- 318 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.
Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.